论文部分内容阅读
目的探讨泮托拉唑与奥曲肽治疗上消化道出血的疗效。方法选取了220例上消化道出血患者,按随机数字表法分为两组,观察组(115例)给予奥曲肽联合泮托拉唑治疗,对照组(105例)给予泮托拉唑治疗,观察两组疗效、围手术期指标、SF-36评分及随访1个月期间不良反应情况,评价泮托拉唑与奥曲肽治疗上消化道出血的疗效。结果治疗后观察组有效率明显高于对照组(P<0.05),观察组出血时间短于对照组,输血量少于对照组;血红蛋白水平,胃液PH值显著高于对照组(P<0.05),治疗前,两组SF-36量表各项评分相比,无统计学差异。治疗后1个月,观察组在生理功能、生理职能、躯体疼痛上评分均明显高于对照组(P<0.05),其余各项评分相比无统计学差异,随访1个月期间,两组不良反应无统计学差异。结论奥曲肽联合泮托拉唑对上消化道出血具有较好疗效,能够迅速止血,减少血液流失和输血量,改善患者生活质量,用药具有安全性,值得临床推广使用。
Objective To investigate the efficacy of pantoprazole and octreotide in the treatment of upper gastrointestinal bleeding. Methods A total of 220 patients with upper gastrointestinal bleeding were selected and divided into two groups according to the random number table. The observation group (115 cases) was given octreotide combined with pantoprazole, and the control group (105 cases) was treated with pantoprazole. Two groups of curative effect, perioperative index, SF-36 score and 1 month follow-up of adverse reactions, evaluation of pantoprazole and octreotide in the treatment of upper gastrointestinal bleeding effect. Results After treatment, the effective rate of the observation group was significantly higher than that of the control group (P <0.05). The bleeding time in the observation group was shorter than that in the control group, and the blood transfusion volume was less than that in the control group. The hemoglobin level and gastric juice PH value were significantly higher than those in the control group (P <0.05) Before treatment, there was no significant difference between SF-36 scores of two groups. One month after treatment, the score of observation group was significantly higher than that of the control group (P <0.05), and there was no significant difference between the other groups. One month after the visit, the two groups Adverse reactions no statistical difference. Conclusions Octreotide combined with pantoprazole has a good curative effect on upper gastrointestinal bleeding, which can quickly stop bleeding, reduce blood loss and blood transfusion, and improve the quality of life of patients. The medication is safe and worthy of clinical application.